CA2434685A1 - Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri - Google Patents

Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri Download PDF

Info

Publication number
CA2434685A1
CA2434685A1 CA002434685A CA2434685A CA2434685A1 CA 2434685 A1 CA2434685 A1 CA 2434685A1 CA 002434685 A CA002434685 A CA 002434685A CA 2434685 A CA2434685 A CA 2434685A CA 2434685 A1 CA2434685 A1 CA 2434685A1
Authority
CA
Canada
Prior art keywords
mixture
residue
added
nmr
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002434685A
Other languages
English (en)
Inventor
Laurence Mulard
Armelle Phalipon
Philippe Sansonetti
Francoise Baleux
Frederic Belot
Cyrille Grandjean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002434685A priority Critical patent/CA2434685A1/fr
Priority to CA002434668A priority patent/CA2434668A1/fr
Priority to US10/563,221 priority patent/US8124380B2/en
Priority to EP04744281A priority patent/EP1642132B1/fr
Priority to PCT/IB2004/002657 priority patent/WO2005003775A2/fr
Priority to EP10011475.0A priority patent/EP2369345B1/fr
Priority to DK10011475.0T priority patent/DK2369345T3/en
Priority to CA2470262A priority patent/CA2470262C/fr
Priority to CA2531023A priority patent/CA2531023C/fr
Priority to DK04744281.9T priority patent/DK1642132T3/da
Priority to AT04744281T priority patent/ATE514087T1/de
Publication of CA2434685A1 publication Critical patent/CA2434685A1/fr
Priority to US13/325,511 priority patent/US9446109B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Saccharide Compounds (AREA)
CA002434685A 2003-07-04 2003-07-04 Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri Abandoned CA2434685A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002434685A CA2434685A1 (fr) 2003-07-04 2003-07-04 Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri
CA002434668A CA2434668A1 (fr) 2003-07-04 2003-07-07 Nouvelle approche pour concevoir des glycopeptides a base de o-specifique polysaccharide de shigella flexneri serotype 2a
EP10011475.0A EP2369345B1 (fr) 2003-07-04 2004-07-02 Glycoconjugués et leur utilisation comme vaccins potentiels contre une infection provoquée par shigella flexneri
EP04744281A EP1642132B1 (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
PCT/IB2004/002657 WO2005003775A2 (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
US10/563,221 US8124380B2 (en) 2003-07-04 2004-07-02 Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri
DK10011475.0T DK2369345T3 (en) 2003-07-04 2004-07-02 Glycoconjugates and their use as potential vaccines against infection with Shigella flexneri
CA2470262A CA2470262C (fr) 2003-07-04 2004-07-02 Glyconconjugues et utilisation conenxe comme vaccins possibles contre l'infection par shigella flexneri
CA2531023A CA2531023C (fr) 2003-07-04 2004-07-02 Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
DK04744281.9T DK1642132T3 (da) 2003-07-04 2004-07-02 Glycokonjugater og deres anvendelse som potentielle vacciner mod infektion med Shigella flexneri
AT04744281T ATE514087T1 (de) 2003-07-04 2004-07-02 Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri
US13/325,511 US9446109B2 (en) 2003-07-04 2011-12-14 Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002434685A CA2434685A1 (fr) 2003-07-04 2003-07-04 Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri

Publications (1)

Publication Number Publication Date
CA2434685A1 true CA2434685A1 (fr) 2005-01-04

Family

ID=33569507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002434685A Abandoned CA2434685A1 (fr) 2003-07-04 2003-07-04 Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri

Country Status (1)

Country Link
CA (1) CA2434685A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114854645A (zh) * 2022-06-10 2022-08-05 陕西师范大学 一种适合沙雷氏菌l-鼠李糖诱导表达系统的应用培养基和培养方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114854645A (zh) * 2022-06-10 2022-08-05 陕西师范大学 一种适合沙雷氏菌l-鼠李糖诱导表达系统的应用培养基和培养方法

Similar Documents

Publication Publication Date Title
US9446109B2 (en) Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri
Pozsgay Synthesis of glycoconjugate vaccines against Shigella dysenteriae type 1
Boltje et al. Chemical synthesis and immunological evaluation of the inner core oligosaccharide of Francisella tularensis
US11191822B2 (en) Pneumococcal polysaccharide-protein conjugate composition
Zhao et al. Conjugation of synthetic trisaccharide of Staphylococcus aureus type 8 capsular polysaccharide elicits antibodies recognizing intact bacterium
KR20200106034A (ko) 클렙시엘라 뉴모니아에 대한 백신
Laverde et al. Synthetic oligomers mimicking capsular polysaccharide diheteroglycan are potential vaccine candidates against encapsulated Enterococcal infections
US10087242B2 (en) Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
Wang et al. Chemical synthesis and immunological evaluation of fragments of the multiantennary group-specific polysaccharide of group B Streptococcus
US10500262B2 (en) Synthetic antigen constructs against Campylobacter jejuni
Qin et al. Recent chemical synthesis and immunological evaluation of glycans related to bacterial lipopolysaccharides
US20240024489A1 (en) Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
CA2434685A1 (fr) Nouvelle approche d'elaboration de glycopeptides a base de polysaccharide o-specifique du serotype 2a de shigella flexneri
Basu et al. Recent chemical syntheses of bacteria related oligosaccharides using modern expeditious approaches
WO1999003871A1 (fr) Vaccin conjugue hexadecasaccharide-proteine contre shigella dysenteriae de type 1
CA2531023C (fr) Glycoconjuges et leur utilisation comme vaccins potentiels contre une infection provoquee par shigella flexneri
US20150290331A1 (en) Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
Jiao Syntheses of carbohydrate antigens expressed by gastric-intestinal bacteria and conjugates thereof
Milhomme et al. Synthetic efforts towards glycoconjugate-based vaccines active against Anthrax
WO2023168520A1 (fr) Prévention/traitement d'une infection par pseudomonas aeruginosa
Jiao An anti-Clostridium difficile vaccine: chemical synthesis of the pentasaccharide repeating unit of polysaccharide PS-I
Schumann Synthesis and Immunological Evaluation of Oligosaccharide-Antigens as Vaccine Candidates for Streptococcus pneumoniae Serotypes 1 and 8
Guo I. Synthetic bacterial lipopolysaccharide core structures as vaccine candidates against Clamydia trachomatis and Yersinia pestis: II. Synthesis of a fungal galectin epitope trisaccharide and the HNK-1 epitope trisaccharide
CA2511084A1 (fr) Conjugues carbohydrate-phosphorylcholine et utilisations vaccinales, therapeutiques et diagnostiques connexes

Legal Events

Date Code Title Description
FZDE Dead